Lataa...
Postantibiotic and Sub-MIC Effects of Exebacase (Lysin CF-301) Enhance Antimicrobial Activity against Staphylococcus aureus
CF-301 (exebacase) is a recombinantly produced bacteriophage-derived lysin (cell wall hydrolase) and is the first agent of this class to enter clinical development in the United States for treating bacteremia including endocarditis due to Staphylococcus aureus. Whereas rapid bactericidal activity is...
Tallennettuna:
| Julkaisussa: | Antimicrob Agents Chemother |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society for Microbiology
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6535547/ https://ncbi.nlm.nih.gov/pubmed/30936103 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02616-18 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|